Why the study?
Does room temperature storage affect the stability of low concentrations of cardiac troponin I measured by an ultrasensitive assay in healthy volunteers and ED patients?
Does room temperature storage affect the stability of low concentrations of cardiac troponin I measured by an ultrasensitive assay in healthy volunteers and ED patients?
Low concentrations of cardiac troponin I are stable in whole blood and serum at room temperature for up to 48 hours, validating the use of high-sensitivity assays for samples with delayed processing.
Answers are grounded in this paper and cite their sources.
Low cTnI remains stable at room temperature; leaves open whether findings generalize to routine clinical workflows or alter troponin-based decisions.
Cardiac troponin I (cTnI)1 is the gold standard biomarker for diagnosing patients with acute coronary syndromes. Expert panels have defined the decision limit at >99th percentile of a reference population and assay imprecision of ≤10%. Prototype ultrasensitive cTnI assays allow accurate detection of low concentrations of cTnI in healthy individuals. However, these novel assays require analytical and biological validation before they can be put into clinical practice. We previously reported the 99th percentile cutoff of 7 ng/L for the Erenna® cTnI immunoassay (Singulex), with the requisite precision. Using a single-molecule counting technology, the limit of detection (0.2 ng/L) surpassed many other commercial assays. The improved limit of detection is not an artifact of nonspecific-binding events (1). We also showed that the increased analytical sensitivity of the assay enabled measurement of the short- and long-term biological variation of cTnI from healthy individuals (2). However, to what extent minute levels of analyte instability may have contributed to this variation was not established. We determined the in vitro stability of cTnI in whole blood and serum over short- and long-term intervals in both healthy subjects and in a small subset of patients who presented to the San Francisco General Hospital Emergency Department. A protocol for the use of leftover blood from routine collections and for collecting blood of healthy subjects was reviewed and approved by the University of California San Francisco Committee on Human Health. Previous reports demonstrated cTnI stability at high concentrations in patients with cardiac injury (3)(4)(5), despite the fact that these samples may contain proteolytic enzymes that are coreleased following cardiac injury. None of these studies used high-sensitivity assays to demonstrate analyte stability at the low concentrations observed in healthy individuals. Because the Erenna cTnI immunoassay has high analytical sensitivity, our study will answer whether differences in clinical study design, such as timing between blood draws, removal of serum or plasma from cells, and subsequent specimen testing procedures, will contribute variability to cTnI measurements. Four milliliters of blood from apparently healthy volunteers who self-reported no cardiac symptoms was drawn into EDTA-plasma and serum separator tubes (SSTs). To assess stability over a short-term period of 6 h, 4 EDTA and 4 SST samples were collected from each of 15 volunteers. The first sample (t = 0) for each specimen type was centrifuged and immediately frozen at −80 °C. The remaining samples were left at room temperature for 2, 4, and 6 h before centrifugation and −80 °C storage. Analyte stability after 1- and 6-h room temperature storage were also assessed in 10 healthy subjects and 12 emergency department patients who presented with chest pain and had low cTnI concentrations. To assess stability over a long-term period of 48 h, we collected 3 EDTA and 3 SSTs from each of 15 volunteers. EDTA plasma samples were either centrifuged and frozen immediately or left at room temperature for 24 or 48 h before spinning and −80 °C storage. SST samples were spun first, then either frozen immediately or left at room temperature for 24 or 48 h before −80 °C storage. Resulting samples were thawed and batch tested using the Erenna cTnI immunoassay. The mean CV was 11% (range 4%–24%) for cTnI measurements over 6 h, and 14% (range 2%–34%) over 48 h (Table 1 ). The variation was similar when compared to other conventional assays. The percent changes over 1 h for healthy subjects and 6 h for chest pain patients were <1% and <3%, respectively. Compared to other conventional assays, analyte variability was not different in this study. A previous experiment performed using the iSTAT assay noted <4% change in cTnI concentration between samples stored refrigerated or at room temperature over 14 days (3). A study using the Immulite system found <15% differences in samples stored with different protocols (4). However, variability among plasma and serum samples determined with the Vidas system at different temperatures was statistically significant (P < 0.0001) (5). In our analysis, the change in analyte concentration per hour during the 6-h interval was minimal [mean 0.001 (SD 0.031) ng/L]. For the long-term, 48-h interval, we noted a small positive increase in the change in analyte concentration per hour [0.015 (0.033) ng/L, or 0.339 (0.793) ng/L per day]. Variation in cTnI above the analytical precision cutoff (≥20% CV) was observed in 17% of short-term and 33% of long-term samples, suggesting that measurements are most precise when freshly prepared samples are used. However, these limits did not exceed the reference change values of −32% and −45% calculated from the biologic variation of cTnI (2), suggesting that minor analyte instability will not lead to results that are clinically relevant. Analyte stability was not affected by sample type in our study, with both whole blood–EDTA plasma and serum samples providing similar measurements. Analyte stability reported by various cTnI assays. LOD, limit of detection. Apple et al. (3). Hafner et al. (4). Di Serio et al. (5). Analyte stability reported by various cTnI assays. LOD, limit of detection. Apple et al. (3). Hafner et al. (4). Di Serio et al. (5). Using serum or EDTA-plasma, low concentrations of cTnI from blood of healthy subjects and emergency department patients appears to be as stable as the high concentrations released from patients with myocardial damage. Although the mechanism of protein release may be different between normal tissue turnover of healthy subjects and that from minor ischemic injury, once cardiac troponin is in the blood itself, there are no differences with respect to stability. These data will be useful for prospective and retrospective cardiovascular studies when measuring low cTnI concentrations using high-sensitivity assays.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: